Hemoglobin concentration, treatment with erythropoiesis-stimulating agents (ESA) and leukocyte counts in the everolimus (EVR) group (n = 35 until month 24, n = 33 at months 36 and 48) and the control group (n = 70).

Erythropoetin alpha, beta and zeta, Darbepoetin alpha and Methoxy-polyethylene-glycol-epoetin beta were summarized as erythropoiesis-stimulating agents (ESA). Month 1: values determined before initiation of EVR. P values were calculated by the two-sample t-test (hemoglobin, leukocyte count) and by the Fisher’s exact test for the ESA treatment.
Hemoglobin concentration, treatment with erythropoiesis-stimulating agents (ESA) and leukocyte counts in the everolimus (EVR) group (n = 35 until month 24, n = 33 at months 36 and 48) and the control group (n = 70).